Mineralys’ Phase 3 blood pressure pill data support potential FDA approval

Elizabeth Cairns

Senior biopharma journalist

Topline pivotal data suggest that Mineralys Therapeutics’ experimental hypertension pill is a good prospect not only for approval but also for widespread adoption as a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mineralys’ Phase 3 blood pressure pill data support potential FDA approval

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial

How bluebird's buyout offer went from $100M upfront to $29M

Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody

Exclusive: Daiichi Sankyo, Johnson & Johnson partner with RNA delivery startup Nosis Bio

What the FDA, NIH hearings tell us about drug and health policy under Trump

Obesity drug development—still room to grow

Min­eralys’ Phase 3 blood pres­sure pill da­ta sup­port po­ten­tial FDA ap­proval

Senior biopharma journalist

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Mineralys’ Phase 3 blood pressure pill data support potential FDA approval